Effect of Glucagon-Like Peptide 1 (7-36 Amide) on Insulin-Mediated Glucose Uptake in Patients With Type 1 Diabetes

Publisher Website
Google Scholar
Abstract
OBJECTIVE—To examine the insulinomimetic insulin-independent effects of glucagon-like peptide (GLP)-1 on glucose uptake in type 1 diabetic patients. RESEARCH DESIGN AND METHODS—We used the hyperinsulinemic-euglycemic clamp (480 pmol · m−2 · min−1) in paired randomized studies of six women and five men with type 1 diabetes. In the course of one of the paired studies, the subjects also received GLP-1 at a dose of 1.5 pmol · kg−1 · min−1. The patients were 41 ± 3 years old with a BMI of 25 ± 1 kg/m2. The mean duration of diabetes was 23 ± 3 years. RESULTS—Plasma glucose was allowed to fall from a fasting level of ∼11 mmol/l to 5.3 mmol/l in each study and thereafter was held stable at that level. Plasma insulin levels during both studies were ∼900 pmol/l. Plasma C-peptide levels did not change during the studies. In the GLP-1 study, plasma total GLP-1 levels were elevated from the fasting level of 31 ± 3 to 150 ± 17 pmol/l. Plasma glucagon levels fell from the fasting levels of ∼14 pmol/l to 9 pmol/l during both paired studies. Hepatic glucose production was suppressed during the glucose clamps in all studies. Glucose uptake was not different between the two studies (∼40 μmol · kg−1 · min−1). CONCLUSIONS—GLP-1 does not augment insulin-mediated glucose uptake in lean type 1 diabetic patients.

This publication has 34 references indexed in Scilit: